Patient's characteristics
| Patient's characteristics | |
|---|---|
| Overall | |
| Number | 18 |
| Age (years, mean) | 44 (SD 8) |
| Gender (male/female) | 7/11 |
| Disease duration (years, mean) | 14 (SD 5) |
| Natalizumab treatment duration (doses) | 43 (SD 18) |
| Prospective PML detection* | |
| Number | 6 |
| Age (years, mean) | 41 (SD 4) |
| Gender (male/female) | 2/4 |
| Disease duration (years, mean) | 15 (SD 3) |
| Natalizumab treatment duration (doses) | 50 (SD 22) |
| Retrospective PML detection | |
| Number | 12 |
| Age (years, mean) | 47 (SD 9) |
| Gender (male/female) | 5/7 |
| Disease duration (years, mean) | 14 (SD 7) |
| Natalizumab treatment duration (doses) | 40 (SD 15) |
| Time before PML symptoms (days) | 78 (SD 58) |
*Data on PML symptoms in the prospective PML group is not given because it is speculative whether the symptoms during follow-up were based on PML, PML-IRIS manifestation and/or PML treatment side effects.
*PML diagnosis based on the American Academy of Neurology PML diagnostic criteria.6
PML, progressive multifocal leukoencephalopathy; IRIS, immune reconstitution inflammatory syndrome; SD, standard deviation.